<DOC>
	<DOCNO>NCT00033657</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy surgery may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness combine radiation therapy two different chemotherapy regimens surgery treat patient esophageal cancer .</brief_summary>
	<brief_title>Radiation Therapy Chemotherapy Before After Surgery Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare pathologic complete response rate patient adenocarcinoma esophagus gastroesophageal junction treat radiotherapy pre- post-operative cisplatin plus paclitaxel versus cisplatin plus irinotecan . - Compare survival outcome patient treat regimen . - Compare toxicity regimens patient . - Compare tolerability adjuvant chemotherapy regimens neoadjuvant chemoradiotherapy patient . - Compare time progression recurrence patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord ECOG performance status ( 0 vs. 1 ) stage disease ( T2-3 , N0 , M0 vs. T1-3 , N0-1 , M0 M1A ) . Patients randomize 1 2 treatment arm . - Arm A : Patients receive neoadjuvant radiotherapy daily , 5 day week , 5 week begin day 1 concurrently neoadjuvant chemotherapy comprise cisplatin IV ( Intravenous ) 2-3 hour follow irinotecan IV 30-60 minute daily day 1 , 8 , 22 , 29 . Four six week completion neoadjuvant chemoradiotherapy , patient undergo surgical resection . A minimum 4 week resection , patient receive adjuvant chemotherapy comprise cisplatin irinotecan day 1 8 . Treatment adjuvant chemotherapy repeat every 3 week 3 course . - Arm B : Patients receive neoadjuvant radiotherapy arm A concurrently neoadjuvant chemotherapy comprise paclitaxel IV ( Intravenous ) 1 hour follow cisplatin IV 2-3 hour daily day 1 , 8 , 15 , 22 , 29 . Patients undergo surgical resection arm A . A minimum 4 week resection , patient receive adjuvant chemotherapy comprise paclitaxel IV 3 hour follow cisplatin day 1 . Treatment adjuvant chemotherapy repeat every 3 week 3 course . In arm , treatment continue absence disease progression unacceptable toxicity . Patients follow 1 month , every 3 month 2 year , every 6 month 3 year , annually 5 year . ACCRUAL : A total 97 patient ( 50 Arm A 47 Arm B ) accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Newly diagnose adenocarcinoma esophagus ( 20 cm incisor ) gastroesophageal junction Stage T23 , N0 , M0 OR Stage T13 , N01 , M0 M1A ( celiac nodal metastasis ) Tumor must consider surgically resectable ( T13 , T4 ) Age &gt; =18 year ECOG Performance status 01 Adequate hematopoietic , hepatic , renal function define follow within 4 week prior randomization : Granulocyte count least 1,000/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL Creatinine clearance least 60 mL/min Prior curatively treat malignancy allow currently diseasefree survival prognosis 5 year Fertile patient must use effective contraception Endoscopy biopsy dilation allow Tumor extend 2 cm cardia Pregnant nursing Other concurrent illness would preclude study therapy surgical resection Concurrent filgrastim ( GCSF ) study radiotherapy Prior chemotherapy Prior radiotherapy Prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>